The FDA approved Gardasil 9 in 2014. The vaccine targets nine genotypes of HPV known to cause cervical cancer as well as vulvar, vaginal and anal cancers and genital warts caused by HPV.
Researchers followed 14,215 women in 18 countries for up to six years after the first vaccine shots to determine the vaccine’s efficacy at preventing the disease. They followed the women for another five years to examine the vaccine’s ability to produce infection-halting antibodies against the nine genotypes of HPV. Half the women were vaccinated with the earlier approved four-valent Gardasil and half with the nine-valent Gardasil 9.
Researchers found Gardasil 9 demonstrated 97.4 percent efficacy in preventing infections and disease caused by the five additional HPV genotypes not included in the four-valent Gardasil vaccine. Additionally, Gardasil 9 vaccination produced similar antibody protection against the four HPV genotypes in Gardasil.
More articles on healthcare quality:
The work behind cleanliness: How to properly verify sonic cleaners
San Diego County health officials declare hepatitis A outbreak public health emergency
Top 10 infection control stories, Aug. 28 – Sept. 1
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
